Global semaglutide eligibility standards based on BMI may not replicate Indian threat patterns, doubtlessly excluding high-risk sufferers who develop heart problems at decrease physique weights |Image used for representational goal solely
| Photo Credit: AFP
The SELECT trial, led by A. Michael Lincoff and published in The New England Journal of Medicine (2023), confirmed that once-weekly semaglutide decreased main cardiovascular occasions by 20% in adults with a physique mass index (BMI) of 27 or larger and pre-existing heart problems, however with out diabetes. The trial enrolled 17,604 contributors and tracked outcomes over almost 40 months.
But making use of this BMI threshold in India may exclude sufferers in danger, says Aditi Kantipuly, doctor, coaching in preventive drugs and public well being resident at McGill University and visiting scholar on the University of New Mexico.
Published – April 08, 2026 02:37 pm IST
